NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Doc, i checked the trial info on clinicaltrials and didn’t see an answer to this question- seems like you might know.

Treatment and control arms received their injections on the same schedule — more closely spaced to begin with, then tapering off to a regular, widely spaced schedule. What happened when a control patient progressed if they were in that later part of the injection schedule that was evenly spaced out — did they get their DcVax-L injections at the pace they had been receiving placebo (ie, spaced out) so that they wouldn’t know they had been on placebo, or did they in essence start over and get the DcVax-L injections closely spaced and then tamper off again? This second option seems like it would unblind the patient, at least locally to the doctor and the crossover patient.
TIA